Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Lantern Pharma Inc (LTRN)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.53-9.31%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for LTRN yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Progress on creating independent AI business entity | Management is progressing on creating an independent AI business entity, scoring 66% on this goal. | Improving | Progress score falls below 50% or project stalls | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative growth business, not an established compounder: it is loss-making and depends on clinical progress and future platform commercialization. The supplied snapshot calls the thesis intact, but confidence is low and the business still faces high risk.
The evidence does not provide a valuation multiple or a clear account of market expectations, so valuation versus peers and what is already reflected in the market cannot be assessed. The company has no reported revenue in the supplied financials and remains loss-making, leaving the expectations gap uncertain.
Near term, execution remains mixed: Q2 2026 showed clinical progress and a lower operating loss, while the supplied data show no recognized AI-platform revenue. A delisting-rule notice, debt issuance, and an unregistered equity sale add risk; a weaker jobs trend or guidance cut could also weigh on the business outlook.
Over the next one to three years, the thesis hinges on whether oncology programs advance into stronger evidence of later-stage outcomes and whether the AI platform produces measurable commercial revenue. Near term, guidance and operating performance matter, while stronger Healthcare-sector results could support the backdrop but would not resolve company-specific execution risks.
LTRN's multi-year view remains possible but fragile, with limited demonstrated commercial progress and substantial execution and listing-related risks. Confidence is low. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in Lantern Pharma Inc's published investment case. The stated target is Capital raises completed with manageable dilution and stable share count. |
| Under Pressure |
| Repeated large equity sales causing heavy dilution |
Dilution event: 1.47M shares at $1.09 vs $0.53 close; Nasdaq delisting notice Sept 2026 registered direct offering of 1.47M shares and unregistered equity sales; Nasdaq delisting notice for low market value. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Maintain or improve earnings trajectory | A primary condition in Lantern Pharma Inc's published investment case. The stated target is EPS loss narrows or stays better than -0.38 in Q3 2026. | Broken | EPS loss worsens beyond -0.38 in Q3 2026 | Diluted EPS: $-0.57 per share FY2026-Q2; GAAP. Published target: EPS loss narrows or stays better than -0.38 in Q3 2026. Reported actuals cannot certify a consensus target without an explicit period and accounting-basis binding. Aug 14, 2026-0.57 USD/share · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-2.02 → $-2.02 · observed estimates
$0.01B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-07-25 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-07-26 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-07-27 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-07-28 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-07-29 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-07-30 | $-2.02 | $0 | 1 / 1 |
| 2026-07-31 | $-2.02 | $0 | 1 / 1 |
| 2026-08-01 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-08-02 | $-2.02 | $0 | 1 / 1 |
| 2026-08-03 | $-2.02 | $0 | 1 / 1 |
| 2026-08-04 | $-2.02 | $0 | 1 / 1 |
| 2026-08-05 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-08-06 | $-2.02 | $0 | 1 / 1 |
| 2026-08-07 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-08-08 | $-2.02 | $0 | 1 / 1 |
| 2026-08-09 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-08-10 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-08-12 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-08-13 | $-2.02 | $0 | 1 / 1 |
| 2026-08-14 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-08-15 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-08-16 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-08-17 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-08-18 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-08-19 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-08-20 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-08-21 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-08-22 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-08-23 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-08-24 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-08-25 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-08-26 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-08-27 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-08-28 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-08-29 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-08-30 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-08-31 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-09-01 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-09-02 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-09-03 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-09-04 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-09-05 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-09-06 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-09-07 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-09-08 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-09-09 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-09-10 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-09-11 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-09-12 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-09-13 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-09-14 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-09-15 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-09-16 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-09-17 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-09-18 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-09-19 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-09-20 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-09-21 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-09-22 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-09-23 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-09-24 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-09-25 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-09-26 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-09-27 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-09-28 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-09-29 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-09-30 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-10-01 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-10-02 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-10-03 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-10-04 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-10-05 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-10-06 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-10-07 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-10-08 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-10-09 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-10-10 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-10-11 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-10-12 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-10-13 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-10-14 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-10-15 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-10-16 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-10-17 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-10-18 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-10-19 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-10-20 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-10-21 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-10-22 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-10-23 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-10-24 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-10-25 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-10-26 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-10-27 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-10-28 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-10-29 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-10-30 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-10-31 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-11-01 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-11-02 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-11-03 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-11-04 | $-2.02 | $14,600,000 | 1 / 1 |
| 2026-11-05 | $-2.02 | $14,600,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.